BioCentury | Oct 2, 2020
Distillery Therapeutics

Blocking a lipid hydrolase for liver fibrosis

...By Claire Quang, Staff Writer DISEASE CATEGORY: HepaticINDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH)Inhibiting ASAH1, an enzyme...
...enzyme that hydrolyzes ceramide, could treat liver fibrosis. In patients with chronic HCV infection, levels of ASAH1...
...NASH induced by a choline-deficient, high-fat diet, a ceramide analog that inhibits ASAH1 or an ASAH1...
BioCentury | Oct 8, 2019

Lysosomal ceramidase ASAH1 identified as Krabbe disease target

...lysosomal ceramidase ASAH1 was able to treat globoid cell leukodystrophy (Krabbe disease) in mice. Systemic ASAH1...
...Krabbe disease. An ASAH1 inhibitor tool compound also extended life span in the model. TARGET/MARKER/PATHWAY: N-acylsphingosine amidohydrolase 1 (ASAH1)...
...Louis, St. Louis, Mo. email: mssands@wustl.edu Claire Quang Washington University School of Medicine in St. Louis BioMarin Pharmaceutical Inc. N-acylsphingosine amidohydrolase 1 (ASAH1)...
BioCentury | Jul 13, 2018
Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised on July 11 CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of...
BioCentury | Jul 12, 2018
Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of 11.9 million shares...
BioCentury | Mar 30, 2018
Clinical News

Edge discontinues sole clinical candidate EG-1962

Edge Therapeutics Inc. (NASDAQ:EDGE) said it will discontinue development of EG-1962 after an IDMC said the candidate was unlikely to meet the primary endpoint in the Phase III NEWTON 2 trial in adults with aneurysmal...
BioCentury | Mar 28, 2018
Clinical News

Edge falls after discontinuing sole clinical candidate

Edge Therapeutics Inc. (NASDAQ:EDGE) plummeted $14.28 (92%) to $1.31 on Wednesday when the company said it will discontinue development of EG-1962 after an IDMC said the candidate was unlikely to meet the primary endpoint in...
BioCentury | Apr 25, 2017
Distillery Techniques

Biomarkers

...KCNN2) (rs337711), Nav1.8 ( PN3 ; SCN10A) (rs6800541), kelch like family member 3 (KLHL3) (rs2967791), N-acylsphingosine amidohydrolase 1 (ASAH1)...
...Harvard, Cambridge, Mass. email: ellinor@mgh.harvard.edu Hongjiang Li Broad Institute of MIT and Harvard Riken Kelch like family member 3 (KLHL3) N-acylsphingosine amidohydrolase 1 (ASAH1) NaV1.8...
BioCentury | Aug 8, 2016
Clinical News

EG-1962: Phase III started

Edge began the double-blind, placebo-controlled U.S. Phase III NEWTON 2 trial to compare a single intraventricular injection of 600 mg EG-1962 vs. standard of care (SOC) -- 60 mg oral nimodipine given every 4 hours...
BioCentury | Feb 22, 2016
Clinical News

EG-1962: Additional Phase I/II data

Additional data from the open-label, dose-escalation, North American Phase I/II NEWTON trial in 72 patients who had an aneurysmal subarachnoid hemorrhage (aSAH) showed that the median intensive care unit length of stay for a single...
BioCentury | Oct 2, 2015
Financial News

Edge, Mirna price IPOs

Edge Therapeutics Inc. (NASDAQ:EDGE) and Mirna Therapeutics Inc. (NASDAQ:MIRN) each began trading Thursday after pricing IPOs. Edge gained $1.94 (18%) to $12.94 after it raised $80.5 million through the sale of 7.3 million shares at...
Items per page:
1 - 10 of 37